Close
Achema

AstraZeneca to enter into European evidence collaboration

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Trump Order to Go Heavy on D2C Pharmaceutical Ads

US President Donald Trump is all set to order...

Is US Planning Executive Order on Chinese Pharma Companies?

It is worth noting that the pharmaceutical sector’s recent...

The Realities of the Nursing Shortage in Rural America

Along with multiple public health crises, the United States...

Green List by FDA to Cut Illegal GLP-1 Active Ingredients

The U.S. Food and Drug Administration has gone on...

AstraZeneca has entered into a three-year collaboration agreement with healthcare information and technology provider IMS Health.

The collaboration will see both companies boost the use of real-world evidence throughout Europe in order to improve the delivery and efficacy of cost-efficient healthcare. AstraZeneca already have a similar partnership effective in the US – a data and research collaboration with WellPoint subsidiary HealthCore.

As part of the partnership, AstraZeneca will receive access to pre-existing electronic healthcare records, with patient details remaining anonymous, including clinical outcome, economic and treatment pattern data. The information will allow the company to identify unmet needs by detailing how current medicines are working in real-world settings across the European market.

AstraZeneca hopes to use the data across its discovery and clinical development programmes, with an emphasis on chronic illnesses. AstraZeneca research and development president Martin Mackay said: “This insight will help us and our healthcare decision-makers to improve the treatment of disease and ensure effective use of medicines to minimise the burden on individuals and healthcare budgets.”

Latest stories

Related stories

Trump Order to Go Heavy on D2C Pharmaceutical Ads

US President Donald Trump is all set to order...

Is US Planning Executive Order on Chinese Pharma Companies?

It is worth noting that the pharmaceutical sector’s recent...

The Realities of the Nursing Shortage in Rural America

Along with multiple public health crises, the United States...

Green List by FDA to Cut Illegal GLP-1 Active Ingredients

The U.S. Food and Drug Administration has gone on...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back